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Background: Blood Oxygen Level Dependent (BOLD) magnetic resonance (MR) is a novel imaging tool that
detects changes in tissue oxygenation. Increases in renal oxygenation in response to a standard 20 mg intravenous
furosemide stimulus have been evaluated to assess kidney viability in patients with renal artery stenosis (RAS). The
effect of prior exposure to furosemide on the ability of BOLD MR techniques to evaluate renal function is unknown.
This study tested the hypothesis that chronic loop diuretic therapy is associated with attenuated responses in renal
tissue oxygenation as measured by BOLD MR with an acute 20 mg intravenous furosemide stimulus in participants
undergoing evaluation for RAS.
Methods: Thirty-eight participants referred for evaluation of RAS were recruited for this study. We examined renal
cortical and medullary BOLD signal (T2*) intensities before and after a 20 mg intravenous furosemide stimulus.
Additionally, we measured changes in renal artery blood flow using phase contrast techniques.
Results: After controlling for covariates age, race, gender, diabetes, glomerular filtration rate, body mass index, and
stenosis severity, daily oral furosemide dose was an independent, negative predictor of renal medullary T2*
response (p = 0.01) to a standard 20 mg intravenous furosemide stimulus. Stenosis severity and ethnicity were also
significant independent predictors of changes in T2* signal intensity in response to an acute furosemide challenge.
Changes in renal blood flow in response to acute furosemide administration were correlated with changes in T2* in
the renal cortex (r = 0.29, p = 0.03) but not the medulla suggesting changes in renal medullary oxygenation were
not due to reduced renal medullary blood flow.
Conclusions: Chronic furosemide therapy attenuates BOLD MR responses to an acute furosemide stimulus in
patients with RAS being evaluated for renal artery revascularization procedures. Thus, patients who are chronically
administered loop diuretics may need a different dosing strategy to accurately detect changes in renal oxygenation
with BOLD MR in response to a furosemide stimulus.
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Improvement in renal tissue oxygenation manifested by
increased Blood Oxygen Level Dependent (BOLD) mag-
netic resonance (MR) signal intensity after intravenous
(IV) furosemide has recently been identified as a potential
noninvasive marker of “renal viability” that may indicate
kidneys most suitable for renal artery revascularization
procedures [1,2]. In these MR procedures, BOLD images
are generally acquired prior to and fifteen minutes after a
standard IV 20 mg dose of furosemide [1-3]. If a kidney
subtended by a renal arterial luminal narrowing ≥70% is
unable to increase tissue oxygenation in response to an IV
20 mg furosemide stimulus, it may be less likely to signifi-
cantly improve its function after renal artery revasculariza-
tion (as evidenced by reduction in systemic arterial
pressure and increased glomerular filtration rate [GFR]).
Importantly however, the potential influence of chronic
oral furosemide treatment on the response to an acute
furosemide stimulus during the BOLD MR imaging pro-
cedure is unknown. This point is important because pa-
tients with severe renal artery stenosis (RAS) receiving
chronic loop diuretic therapy may have an attenuated
BOLD MR response to acute furosemide administration.
If this is the case, an attenuated BOLD MR response to
furosemide could incorrectly be interpreted as evidence
that the patient might not benefit from renal artery revas-
cularization procedures when in fact they may be a suit-
able candidate. In this study, we prospectively evaluated
renal cortical and medullary BOLD MR measures before
and after 20 mg of IV furosemide in patients aged ≥
55 years who were referred for RAS evaluation. We exam-
ined the BOLD MR responses to 20 mg of IV furosemide




This study was approved by the Institutional Review
Board (IRB) at the Wake Forest School of Medicine and
all study participants provided written, witnessed in-
formed consent. We included 38 participants referred
for evaluation of RAS based on existing clinical suspicion
or findings from existing non-invasive imaging studies in-
cluding renal Doppler examinations, contrast angiography
or CT. Participants were ineligible for enrollment if they
exhibited a contraindication for MR (implanted metal,
pacemakers, defibrillators, other electronic devices or
claustrophobia), active acute coronary or cerebral or per-
ipheral arterial symptoms, severe aortic stenosis or other
significant valvular disease, or those with a contraindica-
tion to the receipt of furosemide. After enrollment, GFR
was estimated in each participant using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [4] using the serum creatinine value obtainedfrom a blood draw obtained within four weeks prior to
each MR examination. Participants were asked to abstain
from taking any diuretics including furosemide at least
12 hours prior to the MR scan. The records and clinical
characteristics of each participant were reviewed in
accordance with Wake Forest School of Medicine IRB
policies.
MR Imaging protocol
Comprehensive MR imaging examinations were performed
on a Magnetom Avanto 1.5 Tesla scanner (Siemens
Medical Solutions USA, Malvern, Pennsylvania) using a
phased-array surface coil applied across the abdomen
to optimize signal to noise. Electrocardiographic (ECG)
leads and respiratory gating bellows were applied to ac-
count for cardiac and respiratory motion respectively.
Blood pressure and heart rate were monitored periodically
during the MR examination to ensure hemodynamic
stability.
A three-dimensional (3D), segmented steady-state
free-precession sequence with non-selective radiofre-
quency excitation was utilized to acquire non-contrasted
angiograms of the renal arteries. The fields of view
(FOV) ranged from 30-40 cm to cover the entire abdo-
men in the axial position to obtain 3D volume acquisi-
tions. Imaging parameters included a repetition time
(TR) of 2.3 ms, an echo time (TE) of 1 ms, a 90° flip
angle, a readout bandwidth of 980 Hz per pixel, a 256 ×
256 matrix, and a total of approximately 40-50 3D parti-
tions with a slice thickness of 3 mm. A parallel imaging
technique, generalized autocalibrating partially parallel
acquisition (GRAPPA) with an acceleration factor of 2
was applied to shorten scan times. Percentage stenosis
of each renal artery was visually estimated by a blinded
board-certified cardiologist and cardiovascular imager.
After locating the renal arteries, an image series of the
vessels in double-obliqued cross-sectional orientation
was obtained to ensure a circular lumen throughout the
cardiac cycle to minimize partial volume effects during
image acquisition. Interleaved, phase-contrast gradient-
echo sequences were used to determine cardiac cycle-
dependent measurements of vessel area and velocity
according to previously published techniques from our
laboratory [5]. These sequences were positioned in an
oblique plane 2 cm distal to the origin of the renal artery
at the aorta. These scans utilized 7 mm thick slices with
a 256 × 256 matrix, 32 cm FOV (yielding voxel sizes of
0.94 × 0.94 × 7 mm for the renal artery), a 40° flip angle,
a TR of 11 ms, and a TE of 3.5 ms.
During suspended respiration, three-plane, single-shot,
fast spin-echo localizing images of the kidneys were per-
formed followed by additional scout images oriented
parallel to the coronal axis of each kidney [2]. BOLD im-
aging consisted of a 2-D fast spoiled gradient echo
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30 ms) obtained at each slice location. BOLD imaging
parameters included a slice thickness of 10 mm, a 224 ×
160-192 imaging matrix, a 32-40 cm FOV, a 45° flip
angle, and a TR of 140 ms [6]. The FOV was adjusted
based on participants’ body sizes and the imaging matrix
and TR’s were adjusted in participants with diminished
breath hold capabilities.
BOLD images were acquired during suspended respir-
ation with coronal slices through the middle of each kid-
ney. Signal intensity versus TE data on a voxel by voxel
basis were used to generate parametric images of T2*.
After completion of the initial BOLD acquisitions, each
participant received 20 mg IV furosemide according to
previously published methods [1,2]. Fifteen minutes after
receipt of furosemide, the renal arterial flow (phase con-
trast) and T2* (BOLD) acquisitions were repeated.
After acquisition, images were transferred to a post-
processing station for analysis. A single person blinded
to clinical participant characteristics performed all
image analyses. Images (either BOLD or phase contrast)
were excluded if there was severe motion artifact, bowel
gas artifacts or if image quality was degraded and renal
segments (cortex versus medulla) or renal artery were
not able to be clearly identified. Phase contrast and
BOLD images were analyzed using post-processing in
custom-written MATLAB (The Mathworks, Inc.; Natick,
Massachusetts). The cross-sectional area of the renal ar-
terial lumen was defined on the magnitude image of the
reference scan by a region of interest (ROI) which was
then superimposed on the velocity map for each corre-
sponding frame of the cardiac cycle and the mean veloci-
ties were obtained by measuring the average pixel
intensity within the ROI.
Renal cortical and medullary T2* values were deter-
mined by manually tracing ROI’s on arterial spin labeling
images with the highest corticomedullary differentiation.
Each ROI contained at least 5 voxels. These ROI’s were
then copied onto the corresponding parametric T2*
maps (both pre-and post-furosemide). Care was taken to
ensure that the ROI was drawn in clearly identifiable
cortical or medullary segments. Areas of artifact or cysts
were avoided. These same ROI’s were then copied onto
the post-furosemide images to ensure similar segmental
position within each kidney.
Statistical analysis
All statistical analyses were performed using SAS 9.2
software (SAS Institute, Cary, North Carolina). Subjects
were classified into two groups: chronic furosemide ther-
apy versus furosemide naïve. The dosage of chronic fur-
osemide therapy was also considered as a continuous
covariate. Descriptive statistics were performed on par-
ticipants on chronic furosemide therapy and comparedto furosemide naïve participants. A p-value of < 0.05 was
considered to be statistically significant. Univariate, mul-
tivariable, and backwards stepwise regression analyses
using mixed model procedures, with kidney side and
kidney region considered as repeated measures, were
performed to evaluate the effect of kidney region, age,
gender, ethnicity, estimated GFR, stenosis severity, pres-
ence of diabetes, body mass index, use of ACEI/ARBs,
number of antihypertensive medications, and chronic
daily furosemide dose (total daily dose in mg) on
changes in renal tissue oxygenation as measured by per-
centage change in T2* signal intensities before and after
20 mg IV furosemide administration. Similar statistical
models were used to evaluate the effects of these vari-
ables on percentage changes in main RBF with kidney
side as the only repeated measure. Percentage change in
RBF was determined using the change in the measured
flow from the pre-furosemide image to the post-
furosemide image divided by the pre-furosemide (base-
line) measurement. The correlation between percentage
changes in RBF using phase contrast and percentage
change in renal tissue oxygenation (T2*) was estimated
using Pearson’s correlation coefficient separately within
each kidney region.
Results
A total of 38 participants were evaluated in this study.
Descriptive statistics of the participants, subdivided by
the concurrent use of chronic furosemide therapy are
displayed in Table 1. Participants receiving chronic fur-
osemide therapy exhibited lower GFR’s (p = 0.005), re-
quired more antihypertensive medications (p = 0.0001),
were more likely to be diabetic (p = 0.01), and were less
commonly treated with angiotensin converting enzyme
(ACE) inhibitors or angiotensin receptor blockers (ARBs,
p = 0.006). Among the 15 participants chronically ad-
ministered furosemide, the total daily dose range ranged
from 20 mg daily to 160 mg daily.
Effect of chronic furosemide therapy on T2* response to
acute furosemide administration
Representative MR scans of participants who were or were
not receiving chronic furosemide therapy are shown in
Figure 1. Overall, furosemide naïve participants experi-
enced significant increases in cortical T2* values after the
20 mg IV furosemide stimulus whereas those receiving
chronic furosemide did not (Figure 2). Both furosemide
naïve and recipients of chronic oral furosemide experi-
enced an increase in renal medullary T2* signal intensities
after the 20 mg IV furosemide stimulus albeit with a
strong trend toward attenuation of the response in those
chronically prescribed oral furosemide (p = 0.07).
Using repeated measures multiple regression analyses,
change in total kidney oxygenation (T2*) was univariately






(n = 23) (n = 15)
Age (years) 68 ± 8 69 ± 10 0.49
Race 0.28
White (%) 78 67
African American (%) 22 33
Gender (% male) 35 40 0.65
Body mass index (kg/m2) 29.4 ± 6.5 30.3 ± 7.1 0.56
GFR (mL/min/1.73 m2) 60.1 ± 31.6 44.6 ± 14.7 0.005*
Renal artery stenosis (mean,%)
Left 26 24 0.70
Right 26 21 0.82
Renal blood flow (mean, ml/min)
Left 187 127 0.17
Right 231 196 0.50
Chronic kidney disease stage (n) 0.01*
Stage 1 (GFR > 90) 5 (22%) 0 (0%)
Stage 2 (GFR 60-89) 5 (22%) 2 (13%)
Stage 3 (GFR 30-59) 9 (39%) 9 (60%)
Stage 4 (GFR 15-29) 4 (17%) 4 (27%)
Stage 5 (GFR < 15) 0 (0%) 0 (0%)
Hypertension diagnosis (%) 91 100 0.25
Number of antihypertensive
meds (n)
2.7 ± 1.6 4.3 ± 1.0 0.0001*
Hemoglobin (g/dL) 12.7 ± 2.3 12.1 ± 1.8 0.25
Diabetes diagnosis (%) 30 60 0.01*
Patients on statin therapy (%) 65 73 0.45
Patients on ACEI’s or ARB’s (%) 65 33 0.006*
Mean ± SE are displayed. GFR glomerular filtration rate, ACEI angiotensin
converting enzyme inhibitors, ARB angiotensin receptor blockers.
*represents p<0.05.
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β = - 3.76 ± 1.81, p = 0.04) and chronic daily furosemide
dose (β = - 0.06 ± 0.03, p = 0.04). Multivariable analyses
demonstrated significant negative effects for both re-
gion (β = - 4.06 ± 1.89, p = 0.04) and chronic furosem-
ide dose (β = - 0.08 ± 0.03, p = 0.02) after accounting
for age, GFR, gender, BMI, percentage stenosis of the
renal artery, diagnosis of diabetes, use of ACE inhibi-
tors/ARBs, and number of antihypertensive medica-
tions. There were no significant interaction effects
between the variables kidney region (cortex vs me-
dulla) and total daily furosemide dose or GFR and fur-
osemide dose.
There was a significant difference in the GFR’s of the
two groups (p = 0.01). Therefore, we performed analyses
after excluding the five participants with high normal
renal function (GFR ≥ 90 mL/min/1.73 m2) in order tomake the groups more comparable. Kidney region
(cortex vs medulla, β = -4.23 ± 1.96, p = 0.04) and total
daily furosemide dose (β = -0.06 ± 0.03, p = 0.04) remained
as significant predictors of attenuated T2* signal intensity
changes in response to an acute furosemide stimulus.
Due to the significant effect of kidney region on T2*
changes in response to acute furosemide administration,
we also evaluated covariates within each region of the
kidney. Univariate and backwards stepwise regression
analyses were performed (Table 2). Using backwards
stepwise regression, three variables (ethnicity [p = 0.004],
stenosis severity [p = 0.04, and chronic daily furosemide
dose [p = 0.01]) were significant independent predictors
of changes in T2* signal intensity in response to an acute
furosemide stimulus. The results of our model indicate
that a patient receiving 40 mg of furosemide twice daily
or 80 mg once daily would be predicted to exhibit a 9%
attenuation of the T2* signal intensity response in the
renal medulla to a 20 mg IV furosemide stimulus, as-
suming no differences in the other variables. The associ-
ation between receipt of higher chronic daily doses of
furosemide and attenuated renal medullary T2* signal
intensity changes in response to a 20 mg IV furosemide
stimulus nearly reached statistical significance (r = -0.19,
p = 0.08, Figure 3).
Renal artery blood flow response to acute furosemide
Renal artery blood flow (RBF) was measured before and
after acute 20 mg IV furosemide administration using
phase contrast techniques in the main renal artery. Base-
line RBF was lower, although not statistically significant, in
participants chronically administered oral furosemide com-
pared to furosemide naïve participants (160 ± 14 ml/min
vs. 210 ± 27 ml/min, p = 0.11). This reduction in baseline
RBF was independent of stenosis severity as there was
no difference in stenosis severity between the two groups
(p = 0.69). RBF increased to 238 ± 28 ml/min (p = 0.005) in
furosemide naïve participants. RBF did not significantly
increase from pre to post-furosemide measures in par-
ticipants chronically receiving daily oral doses of fur-
osemide (165 ± 16 ml/min, p = 0.37). Changes in RBF
were moderately correlated with changes in cortical
T2* values (Figure 4, r = 0.29, p = 0.03). There was no
significant correlation between changes in RBF and
changes in renal medullary T2* (r = 0.04, p = 0.74).
Discussion
The results of this study indicate that chronic oral fur-
osemide administration attenuates the increase in renal
medullary oxygenation in response to an acute 20 mg IV
furosemide stimulus measured by BOLD MR, that
higher daily doses of furosemide are associated with re-
duced increases in the medullary BOLD responses to a
standard furosemide challenge, and that changes in RBF
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Figure 1 MR images of the left kidneys of two participants: furosemide naïve (top row) and chronic furosemide administration of
40 mg/day (bottom row). The anatomic images in the panel in the left column are generated from a non-contrast arterial spin labeling
technique in which the renal cortical segments appear gray and the medullary segments appear dark (white arrows). Corresponding T2* maps
representing tissue oxygenation (Blood Oxygen Level Dependent or BOLD) before (middle column) and after (right column) a 20 mg intravenous
furosemide stimulus. On these images the color scale intensity represents the T2* value for that corresponding voxel. As shown, the furosemide
naïve participant increased both cortical and medullary T2* signal intensities in response to a 20 mg intravenous furosemide stimulus by 12%
and 13% respectively. However, the cortical and medullary T2* percent change in signal intensity decreased (bottom right panel) by 7% and 9%
respectively after a 20 mg intravenous furosemide stimulus.
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in the cortex but not in the medulla.
Renal artery stenosis is a complex pathophysiologic
process that can result in malignant hypertension (HTN),
renal dysfunction and exacerbation of congestive heart
failure [7-9]. Renal artery revascularization procedures, ei-
ther surgical or percutaneous, have been utilized to treat
renovascular HTN in patients with malignant HTN, de-
clining renal function, or those who develop pulmonary
edema based on current guideline recommendations [10].
However, less than half of patients who undergo these re-
vascularization procedures actually receive significant clin-
ical benefit defined as improvement in renal function and
GFR, or blood pressure [7]. To date, ideal strategies to
identify patients who will derive a benefit from renal ar-
tery revascularization procedures remain elusive.
Recently, BOLD MR imaging has been evaluated as a
potential tool to determine if a kidney with a renal arterylesion can increase oxygenation in response to a 20 mg
IV furosemide stimulus [1,2]. Small cross-sectional stud-
ies suggest that a kidney with the ability to improve tis-
sue oxygenation (manifested by an increase in BOLD
signal intensity) in response to a furosemide stimulus
may be more likely to benefit from a revascularization
procedure [1,2,11]. Furosemide, a loop diuretic, blocks
transport of the sodium-potassium-2chloride (Na-K-2Cl)
transporter located in the thick ascending limb of the
loop of Henle (TALH) within the renal medulla [12]. Lu-
minal Na + uptake via the apical membrane Na-K-2Cl
transporter is coupled to basolateral membrane trans-
port which depends on Na-K-ATPase activity, an oxygen
(O2)-dependent process [13,14]. Therefore, blocking the
Na-K-2Cl transporter reduces renal medullary O2 con-
sumption and increases tissue oxygenation.
Since many patients with severe renovascular disease
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Figure 2 Bar graph displaying mean± SE renal cortical and medullary BOLD signal intensities (T2*) prior to (light gray) and after (black) a
20 mg intravenous furosemide stimulus in furosemide naïve participants compared with participants chronically receiving furosemide.
Table 2 Univariate and backwards stepwise regression
analyses of percentage change in renal medullary tissue
oxygenation (T2* signal intensity) in response to a 20 mg
intravenous furosemide stimulus











Gender 2.27 (4.31) 0.61
Ethnicity -14.4 (4.61) 0.006* -13.1 (4.09) 0.004*
Stenosis severity (%) -0.12 (0.06) 0.04* -0.11 (0.05) 0.04*
Diabetes diagnosis 0.72 (4.61) 0.88




-0.09 (0.05) 0.09 -0.11 (0.04) 0.01*
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etic use on the BOLD MR response to an acute stimulus
with furosemide. Otherwise, patients receiving chronic
loop diuretic therapy who demonstrate attenuated in-
creases in T2* signal intensities after acute furosemide
administration may be inappropriately deemed less likely
to receive clinical benefit from renal artery revasculariza-
tion procedures. Our results demonstrate that chronic
oral furosemide consumption is associated with attenu-
ated increases in medullary oxygenation after 20 mg of
IV furosemide (Figure 2) despite abstaining from fur-
osemide ingestion greater than 12 hours prior to BOLD
MR examination. The half-life of furosemide is 30 to
60 minutes, therefore 12 hours should be more than ad-
equate time to withhold furosemide. The results of our
model indicate that a patient receiving 40 mg of fur-
osemide twice daily or 80 mg once daily would be pre-
dicted to exhibit nearly a 10% attenuation of the T2*
signal intensity response in the renal medulla to a 20 mg
IV furosemide stimulus, assuming no differences in the
other variables.
Despite worsened renal dysfunction and a higher
prevalence of diabetes in the chronic furosemide group,
pre-furosemide cortical and medullary T2* values were
similar to furosemide naïve participants. This observa-
tion illustrates the point that unless patients have a
critical renal arterial narrowing, the renal cortex and
medulla are able to maintain tissue oxygenation, at least
Figure 3 Scatter plot demonstrating the relationship between
daily oral furosemide dose (x-axis) and the percentage change
in medullary T2* values after 20 mg intravenous furosemide
(y-axis). The circular symbols (●) represent data from a single
participant. The regression equation and line are displayed. The
asterisk (*) represents p <0.05.
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participants receiving chronic furosemide did not signifi-
cantly increase T2* signal intensities in the cortex. Al-
though these participants did exhibit a significant increase
in T2* signal intensities after 20 mg IV furosemide in the
renal medulla compared to pre-furosemide values, they
exhibited attenuated increases in medullary T2* values
compared to furosemide naïve participants (Figure 4).
After adjustment for covariates age, gender, race, GFR,
diabetes, stenosis severity and BMI, number of antihy-
pertensive medications, use of ACE inhibitors or ARBs,
chronic daily furosemide dose was a significant negative














Figure 4 Scatter plot demonstrating the relationship between percen
renal cortical T2* values (x-axis) after 20 mg intravenous furosemide
p-value are displayed.acute furosemide stimulus. Although it did not quite
meet statistical significance (p = 0.07) due to a relatively
small number of participants in this study, total daily
furosemide dose was associated with attenuated T2* sig-
nal intensity changes in response to an acute furosemide
stimulus. However, chronic daily furosemide dose did
not predict the response in the cortex. This finding is
consistent with the site of action of loop diuretics such
as furosemide which act on the TALH [15]. In rodents,
furosemide significantly increased O2 levels measured by
O2-sensitive electrodes in the renal medulla [16]. This
increase in medullary oxygenation was due to decreased
tubular O2 consumption as medullary blood flow was
decreased by nearly 30%.
White race was also associated with significantly attenu-
ated T2* responses in the medulla to an acute furosemide
stimulus. Textor et al. found higher baseline BOLD MR
renal medullary R2* values (inverse of T2*) in African
Americans, compared to whites [17]. After a furosemide
stimulus, however, these R2* levels decreased to the same
values as in whites. These findings suggest increased O2
consumption and TALH Na + reabsorption in African
Americans compared to whites. If whites reabsorb less
Na + in the TALH, they would be expected to have less
inhibition of the Na-K-2Cl transporter in response to
furosemide. Therefore, our findings corroborate those
of Textor et al. suggesting that African Americans have
increased Na + reabsorption in the TALH compared to
whites. The mechanisms involved in the augmented
TALH Na + reabsorption in African Americans are
poorly understood and warrant further study.
Higher chronic furosemide doses were associated, al-
beit weakly, with attenuated T2* responses to an acutelood flow change (%)
r=0.29, p=0.03*
tage change in renal artery blood flow and percentage change in
(y-axis). The regression line, Pearson’s correlation coefficient, and
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statistically significant, it would likely achieve signifi-
cance with a larger study size. This finding is intuitive,
given that with most classes of medications, higher
chronic daily doses reflect altered pharmacokinetics re-
quiring higher acute doses to achieve a desired physio-
logic response.
Renal tissue oxygenation is at least partly dependent
on oxygen delivery via RBF [18,19]. One limitation of
many studies evaluating renal oxygenation with BOLD
MR is the reliance on either iodinated or gadolinium
based contrast administration for determination of RBF.
The former would require a separate imaging examination
(computed tomography [CT]), possibly introducing differ-
ent physiological conditions at separate time points. While
RBF and perfusion can be determined during one single
imaging examination with the administration of gadolin-
ium contrast, this agent is contraindicated in patients with
GFR < 30 ml/min/1.73 m2 due to the risk of nephrogenic
systemic fibrosis [20], thereby limiting the potential appli-
cation of this diagnostic strategy in individuals with pro-
gressed renal dysfunction.
We employed phase contrast techniques to quantify
RBF in each renal artery before and after IV furosemide
to determine whether RBF influenced O2 utilization. In
furosemide naïve participants, RBF increased in response
to 20 mg IV furosemide suggesting vasodilation which
has been reported previously in human studies [21]. In
participants chronically administered furosemide, RBF
tended to be lower at baseline and did not increase after
20 mg IV furosemide. This may reflect the higher preva-
lence of diabetes and/or renal insufficiency in these par-
ticipants. There was no difference in the severity of
stenoses between the two groups.
Change in cortical T2* intensity was correlated with
RBF measures, while there was no correlation observed
in the medulla. Compared to the cortex, the medulla re-
ceives much less blood flow relative to its high metabolic
workload and functions in near-hypoxic conditions at
baseline [22,23]. Therefore, alterations in RBF and subse-
quently O2 delivery should be better tolerated in the cor-
tex due to its abundance of blood flow [24]. Our
findings suggest that the increase in tissue oxygenation
observed in the cortex is likely related to increases in
total RBF and O2 delivery, at least in those not receiving
chronic furosemide therapy. However, we observed in-
creases in medullary tissue oxygenation in response to
an acute furosemide stimulus although this response
was reduced compared to those not receiving chronic
furosemide. The relationship between RBF and oxygen-
ation is complex, particularly in the medulla. Increases
in RBF do increase renal O2 delivery; however, increases
in RBF also increase tubular Na + delivery and transport
resulting in increased metabolic workload [25]. Ourobservations may reflect compensatory mechanisms in the
medulla to maintain homeostasis and potentially downreg-
ulate non-essential metabolic functions in times of reduced
RBF and O2 delivery that may occur with renal arterial
stenoses. Alternatively, RBF may be shunted towards the
medulla during stress conditions to maintain metabolic de-
mands as the cortex is relatively overperfused and is likely
able to better tolerate reductions in total RBF compared to
the medulla. Hence, there is no significant correlation be-
tween total RBF and renal medullary oxygenation unless
RBF is reduced below a critical point which may be ob-
served in severe renal arterial narrowings.
Our study has some limitations. We were unable to
obtain measurements of renal oxygenation by BOLD in
6 of the 76 kidneys due to artifacts (motion or bowel
gas) and poor image quality. RBF measures were not
performed in 12 of the 76 renal arteries due to inad-
equate visualization of the renal artery on phase contrast
velocity maps due to extremely low blood flow or mo-
tion artifact. Second, Na + intake or reabsorption and
water loading conditions were not monitored in our
study and could potentially confound our results. An-
other potential confounder is the higher prevalence of
participants on ACE inhibitors or ARBs in the furosem-
ide naïve group. We attempted to adjust for these factors
in our multivariable analyses. Although these agents the-
oretically may influence renal tissue oxygenation [26],
they did not increase renal issue oxygenation in type 2
diabetic hypertensive patients in a recent study using
BOLD MR imaging with a furosemide stimulus [3]. Be-
cause the GFRs were different between our two groups,
we performed additional analyses with exclusion of five
of the furosemide naïve group with GFR >90 to try to
minimize some of the between group differences which
and the same variables (ethnicity, stenosis severity and
chronic daily furosemide dose) remained as significant
independent predictors of changes in T2* intensity in re-
sponse to an acute furosemide stimulus. Our findings
are consistent with findings published in a study of 280
patients demonstrating no differences in T2* intensities
between different stages of CKD [27]. However, our find-
ings build upon this work by demonstrating no relation-
ship of GFR to changes in T2* signal intensities in
response to an acute furosemide stimulus. Because many
of these factors are closely linked, future studies specific-
ally aimed at determining the effects of chronic furosem-
ide therapy on acute T2* responses to a furosemide
stimulus should be evaluated in better matched cohorts,
possibly with differing doses of furosemide stimuli. It
would be reasonable to investigate administering a larger
intravenous dose of furosemide comparable to the chronic
furosemide dose that patients’ receive chronically to be
able to detect an appropriate increase in renal oxygenation
before determining if a kidney downstream from a severe
Hall et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:17 Page 9 of 10
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Conclusions
Our study demonstrates that chronic furosemide therapy
attenuates BOLD MR responses to an acute furosemide
stimulus in patients with RAS being evaluated for renal ar-
tery revascularization procedures. If BOLD MR with a fur-
osemide stimulus becomes a more widely used method for
determining clinical outcomes for these procedures, careful
attention should be paid to evaluating results in those re-
ceiving chronic loop diuretic therapy. Our findings suggest
that patients on chronic loop diuretic therapy may require
different doses of IV furosemide as a stimulus to detect
changes in renal tissue oxygenation and blood flow before
BOLD MR is widely used to determine renal viability.
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